These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. ERK1/2 can feedback-regulate cellular MEK1/2 levels. Hong SK; Wu PK; Karkhanis M; Park JI Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823 [TBL] [Abstract][Full Text] [Related]
23. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1. Kogut MH; Genovese KJ; He H Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653 [TBL] [Abstract][Full Text] [Related]
24. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524 [TBL] [Abstract][Full Text] [Related]
25. MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. Whitehurst CE; Geppert TD J Immunol; 1996 Feb; 156(3):1020-9. PubMed ID: 8557975 [TBL] [Abstract][Full Text] [Related]
26. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581 [TBL] [Abstract][Full Text] [Related]
27. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling. Kiel C; Serrano L Sci Signal; 2009 Jul; 2(81):ra38. PubMed ID: 19638615 [TBL] [Abstract][Full Text] [Related]
28. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118 [TBL] [Abstract][Full Text] [Related]
29. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
30. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369 [TBL] [Abstract][Full Text] [Related]
31. MEK1/2 dual-specificity protein kinases: structure and regulation. Roskoski R Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953 [TBL] [Abstract][Full Text] [Related]
32. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Romerio F; Riva A; Zella D Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503 [TBL] [Abstract][Full Text] [Related]
34. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Kidger AM; Sipthorp J; Cook SJ Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854 [TBL] [Abstract][Full Text] [Related]
35. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635 [TBL] [Abstract][Full Text] [Related]
36. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473 [TBL] [Abstract][Full Text] [Related]
37. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers. Kinoshita-Kikuta E; Kinoshita E; Ueda S; Ino Y; Kimura Y; Hirano H; Koike T Biochim Biophys Acta Proteins Proteom; 2019 Jan; 1867(1):62-70. PubMed ID: 29753091 [TBL] [Abstract][Full Text] [Related]
38. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Haling JR; Sudhamsu J; Yen I; Sideris S; Sandoval W; Phung W; Bravo BJ; Giannetti AM; Peck A; Masselot A; Morales T; Smith D; Brandhuber BJ; Hymowitz SG; Malek S Cancer Cell; 2014 Sep; 26(3):402-413. PubMed ID: 25155755 [TBL] [Abstract][Full Text] [Related]
39. The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration. Klingauf M; Beck M; Berge U; Turgay Y; Heinzer S; Horvath P; Kroschewski R Biol Cell; 2013 Feb; 105(2):91-107. PubMed ID: 23157514 [TBL] [Abstract][Full Text] [Related]
40. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]